Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
企業コードETON
会社名Eton Pharmaceuticals Inc
上場日Nov 09, 2018
最高経営責任者「CEO」Mr. Sean E. Brynjelsen
従業員数31
証券種類Ordinary Share
決算期末Nov 09
本社所在地21925 W Field Pkwy Ste 235
都市DEER PARK
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号60010-7278
電話番号18477877361
ウェブサイトhttps://etonpharma.com/
企業コードETON
上場日Nov 09, 2018
最高経営責任者「CEO」Mr. Sean E. Brynjelsen
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし